CEO & Majority Shareholder Inject $12.9M via ATM, Extending Cash Runway Amidst Increased R&D
PLSE sits 85% above its 52-week low of $12.56.
Summary
Pulse Biosciences secured $12.9 million from its majority shareholder and CEO via an ATM offering, extending its cash runway and demonstrating strong insider confidence despite an increased net loss in Q1 2026.
Key Events · Financing and Capital Events · PLSE
-
Insider Capital Injection
Majority shareholder Robert Duggan and CEO Paul LaViolette purchased 675,233 shares for $12.9 million through an at-the-market (ATM) offering on May 11, 2026, demonstrating strong insider conviction.
-
Extended Cash Runway
The $12.9 million capital raise, combined with existing resources, is expected to fund operating activities for at least one year, addressing near-term liquidity concerns.
-
Increased R&D Investment
Research and development expenses increased by $2.3 million to $12.6 million in Q1 2026, reflecting continued strategic investment in the nPulse Cardiac Catheter and Surgical Clamp programs.
-
First Product Revenue Reported
The company reported its first product revenue of $0.4 million in Q1 2026 from the limited market release of its Vybrance Percutaneous Electrode System.
Analysis · PLSE · Industrial Applications And Services
Pulse Biosciences reported Q1 2026 financials showing an increased net loss and cash burn, but also its first product revenue of $0.4 million. Critically, the company announced a $12.9 million capital injection from its majority shareholder and Co-Chairman, Robert Duggan, and CEO and Co-Chairman, Paul LaViolette, through an at-the-market (ATM) offering. This insider purchase significantly bolsters the company's liquidity, extending its cash runway for at least one year. The increased R&D expenses reflect continued investment in its core Nano-pulse Stimulation (NPS) technology, particularly the nPulse Cardiac Catheter and Surgical Clamp programs, which have shown compelling clinical data.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 40% of the 1112 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLSE was trading at $23.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.